China Blood Product Industry Report, 2006-2007Research in ChinaApril 4, 2007 25 Pages - SKU: RIC1689688 |
| Countries covered: China Blood product belongs to biological products and is a biological active preparation which collects healthy blood as the raw material and then is made through biological process or separation and purification technologies. Blood products are irreplaceable in the application of medical emergency and prevention & treatment to some specific diseases. China blood product industry is about to see a fast and steady growth: due to the increasing population, high incidence rate of malignant disease and growing national economy, blood product market demands are expected to remain growing at 15% annually; China didn't approve to found new blood product enterprises since 2001, which together with imports limit creates a relatively stable competition environment; after plasma collection stations got restructured, blood product industry chain has become more flexible, which is favor to a long-term development; and industrial supervision will be increasingly strict. Since the state started regulating plasma collection stations in 2004, plasma volume collected has been sliding, to 3,000 tons in 2005 and 2006. As plasma collection stations finished the restructuring, the plasma volume collected has been gradually increasing but plasma supply still falls short presently. The supply and demand are expected to come to a balance by 2008. When the restructuring is over, plasma volume collected is ready to still play an important role for the blood product enterprises to get developed but more important is the ability to manage plasma source. Plasma source management is mainly focused on plasma source scale management and plasma source quality control. Plasma source quality is measured by collected volume of featured plasma, plasma donors' management and guarantee to plasma security. Plasma price keeps growing steadily even after plasma collection stations are restructured, which is because, on the one hand, plasma supply is gradually coming back but still in short; on the other hand, plasma price is quite transparent and even if the cost is added under the counter, it can be seen on the final price. China still can't meet the demands for plasma during 2006-2008 periods; as a result, human serum albumin price will keep high during 2007-2008 periods. Leading enterprises have fostered strong competitive advantages from upstream-quantity, quality and management of plasma collection stations to downstream products' R & D, production and distribution. There will form 2-3 nationwide leader and 5-6 regional leaders in China blood product industry in the future while those small weak enterprises will be phased out. Please Note: Online Download purchase option allows up to 10 users and does not allow printing or editing. This functionality will require a Global Site License. |
More China Biopharmaceuticals Reports
Research Report on Chinese Bio-pharmaceutical Industry, 2012 by
China Research and Intelligence Co., Ltd.
In China, biological products consist of vaccines, blood products, cytokine, diagnostic reagents and other active agents (including toxins, antigens, allergen, and recombinant DNA products, etc.). ...
Biosimilars: China Update by
Datamonitor
Biosimilars: China Update provides analysis on the Chinese biogenerics market. It includes an overview of drivers and resistors to biogeneric uptake, market access strategies, key ...
Biosimilars: China Update by
Datamonitor
Currently, there is no definition, guidance or pathway for biosimilars in China, with domestically manufactured versions of biologics, known as biogenerics. Due to limited R&D ...
Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products China Pharmaceutical Guidebook Series (4) (4th edition) by
Access China Management Consulting Ltd.
The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and ...
Research Report on China's Biopharmaceutical Industry, 2010-2012 by
China Research and Intelligence Co., Ltd.
In China, biological products for human use include bacterial vaccines (including toxoid), viral vaccines, antitoxin and immune serum, blood products, cytokines, in vivo and in ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by
MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>
